key: cord-305659-4pdtqmgp
authors: Kemmner, Stephan; Guba, Markus; Schönermarck, Ulf; Stangl, Manfred; Fischereder, Michael
title: Cyclosporine as preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection
date: 2020-06-04
journal: Kidney Int
DOI: 10.1016/j.kint.2020.05.024
sha: 
doc_id: 305659
cord_uid: 4pdtqmgp

nan

.

The therapeutic regimen consisted of withdrawal of the antimetabolite, conversion to low-dose steroid and introduction of low-dose cyclosporine, azithromycin and hydroxychloroquine. He required mechanical ventilation for four days until his general condition improved significantly and the patient could be discharged after 17 days with stable allograft function. Therefore, switching to a Cyclosporine-based immunosuppression may represent another therapeutic option in the case of COVID-19 infection following kidney transplantation.

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

COVID-19 infection in kidney transplant recipients

Early experience with COVID-19 in kidney transplantation

Cyclosporin A inhibits the replication of diverse coronaviruses